SLC5A2 and diabetes mellitus: These mechanisms, along with lifestyle factors like physical inactivity and dietary habits highlight the importance of targeted interventions to mitigate these risks including the use of sodium-glucose co-transporter-2 (SGLT2) inhibitors, a novel therapeutic choice in diabetes management that provides glycemic control through renal glucose excretion while offering significant cardiovascular benefits [38,39,40].